Overview

Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis

Status:
Withdrawn
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
Dalbavancin for Pediatric Osteomyelitis
Phase:
Phase 3
Details
Lead Sponsor:
Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)
Treatments:
Cefazolin
Dalbavancin
Nafcillin
Oxacillin
Teicoplanin
Vancomycin